drugset / Trial / NCT02273960
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
Timeline
- Start
- 2014-11-17
- Primary completion
- 2018-01-22
- Completion
- 2018-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LETOLIZUMAB | Monoclonal antibody | 75 mg | Intravenous |
| Subject | LETOLIZUMAB | Monoclonal antibody | 225 mg | Intravenous |
| Subject | LETOLIZUMAB | Monoclonal antibody | 675 mg | Intravenous |
| Subject | LETOLIZUMAB | Monoclonal antibody | 1500 mg | Intravenous |